Items Tagged ‘crpc’

June 1st, 2015

Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer

By

The prostate cancer vaccine Prostvac® (rilimogene galvacirepvec/rilimogene glafolivec) may be active in combination with Yervoy® (ipilimumab) in the treatment of metastatic prostate cancer that does not respond to hormone therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Prostate cancer is a hormonally sensitive disease that can […]

View full entry

Tags: castration resistant, crpc, glafolivec, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Prostvac, Yervoy


September 18th, 2014

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

By

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer […]

View full entry

Tags: castration-resistant prostate cancer, crpc, News, odm-201, Prostate Cancer, Refactory/Recurrent Prostate Cancer